Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023

At € 10.9 million or € 0.52 per share, net income was € 3.5 million or 25% lower than in the same period last year. Currency effects in particular reduced the result by around € 2.0 million compared with the previous year. Moreover, increased expenses for future projects in the field of diagnostics and therapy in nuclear medicine had an additional impact.

In the Medical segment, sales in the first half of the year amounted to € 52.6 million, around € 11.1 million or 27% above the previous year's level. Main growth driver continued to be the business with pharmaceutical radioisotopes, with sales of laboratory equipment also continuing to increase.

The Isotope Products segment generated sales of € 65.3 million, € 0.6 million lower than in the first six months of 2022. Almost all main product groups remained stable, however, high-margin sales of radiation sources for applications in the energy sector recorded a weaker first half than in the previous year.

The forecast for the financial year 2023 published on March 30, 2023 remains unchanged. The Executive Board continues to expect sales of just under € 230 million and net income of around € 25 million.

The complete quarterly report can be viewed here:
www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz223e.pdf

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.